PubMed Health⌕ Search

PubMed · 10592580

Treating Helicobacter pylori.

Abstract

BACKGROUND: The treatment for Helicobacter pylori infection has changed continuously during the past decade and recommended treatments have not always been readily available in primary care. These factors have contributed to confusion and considerable variation in prescribing. OBJECTIVE: This short review outlines the key aspects of current treatment of H pylori. DISCUSSION: With the advent of single script, effective therapies, there should be more uniformity in treating this common infection. With appropriate choice of therapy and patient counselling to maximise compliance, excellent H pylori eradication rates are achievable in general practice.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P H Katelaris. 1999. Treating Helicobacter pylori.. https://pubmed.ncbi.nlm.nih.gov/10592580/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years?

Primary gastric (PG) lymphomas are generally non-Hodgkin lymphomas (NHL). They represent 5% of gastric malignancies and show an apparently increasing incidence worldwide. The most common histological subtypes are diffuse large B-cell and marginal zone B-cell NHL of the mucosa-associated lymphoid tissue (MALT)-type. Pathogenesis is often related to Helicobacter pylori infection (HPI). There is still no consensus on the optimal treatment for PG lymphoma. Nowadays surgery is limited to rare cases and radiotherapy--combined or not with chemotherapy--represents an effective therapeutic option ensuring long-term, organ-salvage benefits mainly in aggressive histological subtypes. Additionally, the description of MALT lymphomas has made the situation even more complex, because antibiotics alone can induce lasting remissions in those cases associated with HPI. Consequently, a global therapeutic approach to the cure of PG-NHL has completely changed over the last 10 years: innovative, conservative options to reduce treatment toxicity, thus preventing systemic relapses, have made their appearance and are on the rise.

Helicobacter Infections↗